IFR200 for a Cytomegalovirus (CMV) prediction the probability of viral transmission to the fetus.

IFR200,  a Cytomegalovirus (CMV) is predicting viral transmission to the fetus probability.

2% of the pregnant woman are diagnosed as primary infected with CMV known also as  human herpesvirus-5 (HHV-5).  CMV spreads from person to person through body fluids, such as blood, saliva, urine, semen and breast milk. the mother’s symptoms may include fever, sore throat, fatigue, and swollen glands. These symptoms are similar to those of other illnesses, so most people are not aware that they are infected with CMV. 90% of  babies born (1.8% of pregnant woman) with CMV (in other words, “congenital” CMV) never develop symptoms or disabilities. Over 10% (0.2% of pregnant woman) will bear permanent symptoms such as hearing Loss, vision loss, mental disability, small head, lack of coordination etc. it has been established that only 40% from the primary infected pregnant woman are transmitting the CMV to the fetus.

Using Genefron’s technology, it has been predicted that pregnant women with primary cytomegalovirus (CMV) infection with high anti viral respond will not transmit (~60%) the virus to the fetus.   Genefron kit (approved for use in Israel) has been able to, detect in the mothers blood sample, transmitters/ non-transmitters women in more than 95% accuracy, which may prevent unnecessary termination of pregnancies or close surveillance on fetus development. see results below. The IFR 200  has CE and The Israeli Ministry of Health approval for market it in Israel. It is available in Israel.

For questions – please apply to:


Prediction results  parameters










Comments are closed.